Etana Receives Ministry of Health Award as an Outstanding Institution in National Vaccine Development

PT Etana Biotechnologies Indonesia (Etana) has once again marked a significant milestone in strengthening Indonesia’s national healthcare industry. Etana received an award from the Ministry of Health of the Republic of Indonesia recognizing the company as an Outstanding Institution for its contribution to domestic vaccine development and production.

The award was presented by the Vice Minister of Health of the Republic of Indonesia, dr. Dante, and received by Indra Lamora, Director of the Anti-Infectious Business Unit of PT Etana Biotechnologies Indonesia, during the HAI FEST 2025, held as part of the National Health Day commemoration at Balai Kartini, Jakarta.

This recognition was granted in appreciation of Etana’s achievement as the first vaccine manufacturer in Indonesia to locally produce mRNA vaccines and Pneumococcal Conjugate Vaccine (PCV-13), as well as its strong commitment to the development of a Tuberculosis (TB) vaccine, which has currently entered Phase 1 clinical trials.

These achievements underscore Etana’s strategic role in supporting national pharmaceutical self-reliance, particularly through the introduction of advanced vaccine technologies that were previously dependent on imports. Local production of mRNA and PCV-13 vaccines not only strengthens national health security but also enhances sustainable and equitable access to vaccines for the Indonesian population.

Furthermore, Etana’s involvement in TB vaccine development represents a crucial step in addressing one of Indonesia’s most pressing public health challenges. As tuberculosis remains one of the country’s highest-burden infectious diseases, the ongoing Phase 1 clinical trial is expected to contribute to long-term efforts toward TB control and elimination.

The Ministry of Health acknowledged Etana as an institution that consistently upholds innovation, collaboration, and strict compliance with quality and regulatory standards, spanning the entire value chain from research and clinical development to manufacturing. The award reflects the government’s confidence in the capabilities of Indonesia’s domestic biopharmaceutical industry.

Through this achievement, Etana reaffirms its commitment to advancing biotechnology-based healthcare solutions, strengthening collaboration with government, academia, and global partners, and contributing meaningfully to the development of a resilient, innovative, and globally competitive national healthcare ecosystem.